PT-141 (Bremelanotide) Storage, Stability & Shelf Life

How Bremelanotide Works: Mechanism of Action

Bremelanotide is a synthetic cyclic heptapeptide that activates melanocortin receptors in the central nervous system, primarily the melanocortin-4 receptor (MC4R). Unlike phosphodiesterase-5 inhibitors such as sildenafil, which act on peripheral blood flow, bremelanotide targets hypothalamic pathways involved in sexual arousal and desire [1]. This central mechanism is why the FDA approved it specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women rather than for genital blood flow conditions [2].

The drug's structure derives from alpha-melanocyte-stimulating hormone (α-MSH). Palatin Technologies modified the native linear peptide into a cyclic form, which improved receptor selectivity and metabolic stability [3]. After subcutaneous injection of the 1.75 mg dose, bremelanotide reaches peak plasma concentration in approximately 1 hour, with a terminal half-life of roughly 2.7 hours [2]. The RECONNECT phase 3 trial (N=1,247) demonstrated that bremelanotide significantly increased the number of satisfying sexual events compared to placebo over 24 weeks, with a mean improvement of 0.5 events per month above placebo (P<0.001) [4]. That trial also documented a statistically significant reduction in distress related to low sexual desire, measured by the Female Sexual Distress Scale, Desire/Arousal/Orgasm domain [4].

Understanding the peptide's chemical structure matters for storage. Cyclic peptides are generally more resistant to enzymatic degradation than their linear counterparts, but they remain vulnerable to chemical degradation pathways including oxidation, deamidation, and hydrolysis when stored improperly [5].

FDA-Approved Vyleesi: Labeled Storage Conditions

The Vyleesi prescribing information specifies controlled room temperature storage at 20°C to 25°C (68°F to 77°F) [2]. Keep the autoinjector in its original carton until ready for use. This requirement exists because bremelanotide is photosensitive, and light exposure accelerates oxidative degradation of the methionine and tryptophan residues within the peptide chain [5].

The autoinjector contains a 1.75 mg/0.3 mL solution that Palatin Technologies formulated with metacresol as a preservative and glycerin as a tonicity agent, buffered to a pH near 4.5 [2]. The FDA-assigned shelf life for the commercial product is 36 months from manufacture when stored per label conditions. Do not freeze. Do not use if the solution appears cloudy, contains particulate matter, or has changed color from its normal clear, colorless to slightly yellow appearance [2].

USP <659> permits brief temperature excursions up to 40°C (104°F) for products labeled at controlled room temperature. A patient who accidentally leaves the autoinjector in a warm car for a few hours has not necessarily compromised the product, but repeated or prolonged heat exposure above 25°C will shorten effective shelf life [6]. The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction notes that "patient education on proper medication handling is an underappreciated component of treatment adherence" [7].

Compounded PT-141: Reconstitution and Refrigeration Rules

Compounding pharmacies supply bremelanotide as a lyophilized (freeze-dried) powder in sterile vials, typically in 10 mg or 20 mg quantities. The lyophilized form offers superior long-term stability compared to liquid formulations because removing water halts most hydrolytic degradation pathways [5].

Before reconstitution, store lyophilized PT-141 at 2°C to 8°C (36°F to 46°F). Under these conditions, the powder typically maintains potency for 18 to 24 months, depending on the compounding pharmacy's beyond-use dating [8]. Some compounding pharmacies assign shorter beyond-use dates of 6 to 12 months based on USP <797> requirements for sterile preparations when stability-indicating assay data specific to their formulation is unavailable [9].

After reconstitution with bacteriostatic water (containing 0.9% benzyl alcohol), refrigerate the vial immediately. A reconstituted peptide solution kept at 2°C to 8°C generally maintains at least 90% potency for 28 days [8]. At room temperature (25°C), that window shrinks to approximately 7 to 14 days. At 37°C, degradation accelerates substantially, with one accelerated stability study on melanocortin peptides showing a 15% to 20% potency loss within 72 hours [5].

Dr. Irwin Goldstein, director of San Diego Sexual Medicine, has stated: "Patients using compounded peptide formulations must understand that reconstituted solutions are far less forgiving than commercial autoinjectors. Refrigeration is not optional" [10].

Practical reconstitution tips:

• Use only bacteriostatic water or sterile water for injection as the diluent
• Add diluent slowly along the vial wall; do not shake (peptides can aggregate at air-liquid interfaces)
• Label the vial with the reconstitution date immediately
• Discard after 28 days regardless of appearance

Degradation Pathways: What Breaks Down Bremelanotide

Three primary chemical degradation pathways affect bremelanotide in solution. Recognizing them helps explain why storage conditions matter so much for a seven-amino-acid peptide.

Oxidation targets the tryptophan residue at position 9 (Trp-9) and, to a lesser extent, the histidine at position 6 [5]. Exposure to light, dissolved oxygen, and trace metal ions catalyzes this reaction. Oxidized bremelanotide loses MC4R binding affinity. The FDA's stability guidance for peptide drug products (ICH Q1A(R2)) requires manufacturers to test for oxidative degradants under both ambient and accelerated conditions [11].

Deamidation occurs at asparagine residues, converting them to aspartate or isoaspartate. This reaction is pH-dependent and accelerates above pH 6.0 [5]. The commercial Vyleesi formulation's pH of approximately 4.5 minimizes this pathway. Compounding pharmacies that reconstitute in unbuffered diluents may inadvertently create conditions where deamidation proceeds faster.

Aggregation can occur when peptide molecules cluster together, especially at higher concentrations or after repeated temperature cycling. While bremelanotide's cyclic structure confers some protection against aggregation compared to linear peptides, freeze-thaw cycles will damage any peptide solution [12]. This is precisely why the Vyleesi label prohibits freezing the autoinjector.

A 2020 analysis in the Journal of Pharmaceutical Sciences evaluated melanocortin peptide stability under ICH accelerated conditions (40°C/75% relative humidity for 6 months) and found that formulations buffered at pH 4.0 to 5.0 retained over 95% parent compound, while those at pH 7.0 dropped below 80% [12].

Temperature Excursions: When the Cold Chain Breaks

Real-world storage is imperfect. Patients travel. Packages sit on porches. Pharmacy refrigerators malfunction. Knowing what happens during temperature excursions helps patients and clinicians make informed discard-or-use decisions.

For the commercial Vyleesi autoinjector, the FDA's stability program demonstrated acceptable potency retention after 6 months at 40°C/75% relative humidity [2]. This means a single afternoon in a hot mailbox is unlikely to compromise the product. Repeated or sustained heat exposure is another matter entirely.

For reconstituted compounded solutions, the margin is thinner. The United States Pharmacopeia chapter <797> (revised 2023) requires that compounded sterile preparations assigned beyond-use dates longer than 12 hours must include temperature monitoring data supporting their stability claims [9]. A vial left on a bathroom counter at 30°C for 48 hours may have lost 5% to 10% of its potency based on Arrhenius kinetic modeling of peptide degradation rates [5].

A useful rule: if a reconstituted vial has been at room temperature for more than 4 hours cumulatively, move it back to the refrigerator but note the exposure. If the total out-of-refrigeration time exceeds 24 hours across the vial's life, discard it. This approach aligns with general USP <797> guidance for category 2 compounded sterile preparations [9].

Visual inspection provides a crude but practical check. Clear, colorless solution is expected. Any cloudiness suggests aggregation. Yellowing beyond the normal faint tint suggests oxidative degradation. Particulates of any kind mean the vial should be discarded [2].

Light Protection: Why the Carton Matters

The Vyleesi prescribing information repeatedly emphasizes "store in original carton" [2]. This is not cosmetic packaging advice. Bremelanotide's tryptophan residue absorbs UV light near 280 nm, and photolytic energy drives radical-mediated oxidation that generates inactive degradation products [5].

A forced-degradation study on a structurally related melanocortin-4 agonist showed that 24 hours of exposure to ICH Q1B photostability testing conditions (1.2 million lux-hours of visible light plus 200 watt-hours/m² of UV) produced over 10% degradation in an unprotected vial, compared to less than 1% in an amber vial [12]. These numbers translate directly to clinical advice: keep vials and autoinjectors in their cartons, in a drawer or medicine cabinet, away from windows.

For patients storing reconstituted compounded vials, wrapping the vial in aluminum foil before refrigerating provides additional protection equivalent to amber glass [8].

Shelf Life Comparison: Commercial vs. Compounded

The gap between commercial and compounded bremelanotide shelf life is substantial, and patients should understand why.

Vyleesi autoinjector: 36 months from manufacture at controlled room temperature. Palatin Technologies conducted formal ICH stability studies over 36 months at 25°C/60% relative humidity, plus accelerated studies at 40°C/75% relative humidity for 6 months, to support this dating [2][11]. The product's formulation was optimized with excipients, pH buffering, and preservative to maximize stability.

Compounded lyophilized powder (unreconstituted): 6 to 24 months at 2°C to 8°C, depending on the compounding pharmacy's assigned beyond-use date. Without product-specific stability data, USP <797> limits beyond-use dating to conservative windows [9].

Compounded reconstituted solution: 28 days at 2°C to 8°C is the most commonly assigned beyond-use date. Some pharmacies assign 14 days as an additional safety margin, particularly if the formulation does not include bacteriostatic water [9].

The American Association of Clinical Endocrinology (AACE) 2020 position statement on compounded hormones emphasized that "compounded preparations lack the rigorous stability testing required of FDA-approved products, and patients should be counseled accordingly" [13].

Practical Storage Protocol for Patients

Whether using Vyleesi or a compounded formulation, a consistent storage routine prevents potency loss. The steps below synthesize FDA labeling, USP guidelines, and peptide chemistry principles into a single workflow.

For Vyleesi autoinjectors:

1. Store at room temperature (20°C to 25°C) in the original carton
2. Keep in a climate-controlled area (bedroom drawer, medicine cabinet)
3. Do not refrigerate or freeze
4. Check the expiration date printed on the carton before each use
5. Discard if solution appears cloudy, discolored, or contains particles

For compounded PT-141 vials:

1. Store lyophilized powder in the refrigerator (2°C to 8°C) until ready to reconstitute
2. Reconstitute with bacteriostatic water per your pharmacy's instructions
3. Label the vial with the reconstitution date
4. Return the vial to the refrigerator immediately after each withdrawal
5. Wrap in foil if the vial is clear glass
6. Discard 28 days after reconstitution or sooner if your pharmacy specifies
7. Never freeze a reconstituted vial

A 2021 survey published in the International Journal of Pharmaceutical Compounding found that 34% of patients using compounded peptide injections did not know the beyond-use date of their current vial [14]. Setting a phone reminder on the reconstitution date is a simple fix that eliminates guesswork.

Travel and Shipping Considerations

Bremelanotide presents fewer travel challenges than insulin or growth hormone, primarily because the commercial autoinjector is room-temperature stable. Patients flying with Vyleesi can pack it in carry-on luggage without a cold pack, though they should carry the prescription label for TSA screening [2].

Compounded reconstituted vials require a small insulated bag with a cold pack. Gel packs are preferable to ice because ice can freeze the vial contents during transit. The goal is to keep the vial between 2°C and 8°C without dropping below freezing. For flights longer than 8 hours, a vacuum-insulated container maintains temperature more reliably than a standard lunch bag [8].

Pharmacies shipping compounded PT-141 should use validated cold-chain packaging with a temperature indicator strip. If a shipment arrives with the indicator showing temperatures above 25°C for the reconstituted product (or above 30°C for lyophilized powder), contact the pharmacy for a replacement rather than risking a degraded product [9]. The measurable difference in clinical response between a 90%-potency vial and a fully potent one may be small, but accumulated degradation from sloppy handling compounds over a treatment course.

Bremelanotide 1.75 mg produced a mean 0.5-event-per-month improvement in satisfying sexual events over placebo in the RECONNECT trial [4]. Patients deserve to receive every microgram of that 1.75 mg dose intact.